Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study Susan L. McElroy, James I. Hudson, Julie A. Capece, Karen Beyers, Alan C. Fisher, Norman R. Rosenthal Biological Psychiatry Volume 61, Issue 9, Pages 1039-1048 (May 2007) DOI: 10.1016/j.biopsych.2006.08.008 Copyright © 2007 Society of Biological Psychiatry Terms and Conditions
Figure 1 Population Flow Diagram. *Safety: all randomized patients for whom at least one post-baseline safety measure was available. †ITT: all randomized patients who received study medication and had at least one valid post-baseline efficacy evaluation. ‡mITT: all ITT patients excluding those with ≥ 1 major inclusion/exclusion violation (no diagnosis of binge eating disorder [BED]; did not have ≥ 3 binge days/week at baseline; had baseline body mass index [BMI] < 30 kg/m2; or Montgomery-Åsberg Depression Rating Scale [MADRS] > 24). §Completers: all randomized patients who completed all study visits up to and including visit 10 and exceeded 99 days of taking study medication. Biological Psychiatry 2007 61, 1039-1048DOI: (10.1016/j.biopsych.2006.08.008) Copyright © 2007 Society of Biological Psychiatry Terms and Conditions
Figure 2 The mean number of binge eating days/week. Biological Psychiatry 2007 61, 1039-1048DOI: (10.1016/j.biopsych.2006.08.008) Copyright © 2007 Society of Biological Psychiatry Terms and Conditions
Figure 3 The median number of binge eating days/week. Biological Psychiatry 2007 61, 1039-1048DOI: (10.1016/j.biopsych.2006.08.008) Copyright © 2007 Society of Biological Psychiatry Terms and Conditions
Figure 4 The mean number of binge eating episodes/week. Biological Psychiatry 2007 61, 1039-1048DOI: (10.1016/j.biopsych.2006.08.008) Copyright © 2007 Society of Biological Psychiatry Terms and Conditions
Figure 5 Body mass index. Biological Psychiatry 2007 61, 1039-1048DOI: (10.1016/j.biopsych.2006.08.008) Copyright © 2007 Society of Biological Psychiatry Terms and Conditions